Zacks Industry Outlook Highlights: Medtronic, Boston Scientific, St. Jude Medical, Haemonetics and Cyberonics

For Immediate Release

Chicago, IL – August 25, 2010 – Today, Zacks Equity Research discusses the Medical Device industry, including Medtronic Inc. (MOT), Boston Scientific Corporation (BSX - Analyst Report), St. Jude Medical Inc. (STJ - Analyst Report), Haemonetics Corporation (HAE - Analyst Report) and Cyberonics Inc. (CYBX - Analyst Report).

 

A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/39211/Medical+Devices+Industry+Outlook+-+August+2010

In our portfolio, we see growth potential in companies dealing with cardiovascular devices, Neuro and blood-related products. Names in this list include Medtronic Inc. (MOT), Boston Scientific Corporation (BSX - Analyst Report), St. Jude Medical Inc. (STJ - Analyst Report), Haemonetics Corporation (HAE - Analyst Report) and Cyberonics Inc. (CYBX - Analyst Report). Although these companies have Neutral ratings, they remain well placed in the current environment. We will closely monitor their performances in the current quarter for possible upgrades.

Big-Three MedTechs Lead the Way

The above-listed companies are producers of life-sustaining products and are less affected by economic turbulence. As evident from the most recent quarter results, some of these companies have been successful in weathering the storm (pricing, currency and procedure growth headwinds) in the cardiovascular space in the wake of recovery.

These companies are all leading players in their respective fields and are potential winners in the long run. In particular, with a slew of new products, the big three players (MDT, BSX and STJ) in the implantable cardioverter defibrillator (ICD) market are well positioned to gain market share, despite the sluggish business environment.

Among these names, Medtronic has a diversified presence in Cardiovascular, Neuro, Spinal, Diabetes and ENT. Boston Scientific is the leader in the drug eluting stent (DES) market and is better placed with the recent resolution of all issues cited in its 2006 FDA corporate warning letter regarding serious regulatory problems and corrective actions at three of its facilities. The company’s return to the ICD market (after one month absence due to product recall) represents another boost. Moreover, Boston Scientic’s restructuring initiatives are expected to contribute to the bottom-line moving forward.

St. Jude is poised to grow its market share in the CRM segment (especially in ICDs) driven by its new Fortify and Unify lines of devices. Moreover, we are optimistic about the emerging opportunity in intravascular imaging market, enabled by the company’s LightLab acquisition in July 2010.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5510.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5511.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

 

 

Read the full analyst report on MDT

Read the full analyst report on BSX

Read the full analyst report on STJ

Read the full analyst report on HAE

Read the full analyst report on CYBX